Aiman Moldasheva graduated from University of Toronto with Bachelor of Science in Pharmacology and Biomedical toxicology in 2016. She did her bachelor thesis at the Structural Genomics Consortium (Toronto, Canada), where she was working with an “in silico” method to predict possible off-targets of epigenetic chemical probes.

From 2016 to 2017 she has been working first as a specialist and then as a manager of the international legislation in the field of medicines and medical devices at the National center  of expertise for medicines, medical devices and medical equipment of the Ministry of Health of the Republic of Kazakhstan. She was responsible for harmonization of the Kazakhstani legislation in the field of medicines regulation with guidelines of EMA, FDA and ICH as well as development of guidelines and regulations for the common medicines market of  Eurasian economic union.

In 2019, she obtained a Master’s degree in Toxicology  from University of Potsdam, Germany. While doing her Master’s degree she has been working part-time as a research assistant at the German Institute of Human Nutrition, where she also did her master thesis research. For her master thesis she was evaluating plasma redox biomarkers (protein carbonyls, 3-nitrotyrosine and malondialdehyde) and was assessing skeletal muscle tissue quality in patients the  aortic valve disease and the coronary artery disease. In 2019, she also had a three month internship in the Federal Institute for Drugs and Medical Devices (Bonn, Germany), where she conducted a research on exosomal miRNA from human keratinocytes as biomarkers for dermatologic adverse effects of anticancer drugs.

She is also an alumna of the Bolashak (2011) and the DAAD (2017) (German academic exchange service) scholarships.